Decreased levels of ARID2 and PBRM1 correlated with elevated cytotoxic activity contributed by CD8 positive T cells in human cancers, and improved response to immune checkpoint blockade in the Pbrm1‐deficient B16F10 animal model of melanoma.[116] Complementary work by Miao, et al.[121] demonstrated significantly improved clinical response to immune checkpoint inhibitors in patients with metastatic clear cell renal cell carcinomas that harbor loss‐of‐function mutations in PBRM1. Here, PBRM1 is linked to melanoma.